PHARMA TECH

Pharmacy Management System Project in Python Source Code

May 21, 2022

Pharmacy Management System Project in Python Source Code What is Pharmacy Management System Project in Python

Spotlight

Alnylam Pharmaceuticals

We are developing an innovative, entirely new class of medicines called “RNAi therapeutics” to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNA interference (RNAi), and a bold vision that this discovery could be used to silence disease-causing genes upstream of today’s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn’t have to wait for hope.

OTHER VIDEOS

AI accelerated drug discovery

video | May 20, 2022

AI accelerated drug discovery, allowing for a fast-track discovery and repurposing of existing molecule, intelligent clinical design and coupled with in-house manufacturing....

Watch Now

Prescription Management System in SwilERP Pharmacy Software

video | May 27, 2022

Prescription Management is an essential task for the Pharmacist. The Prescription management feature of SwilERP Pharmacy Software enables the Pharmacists to create and maintain the medical records quickly and accurately evaluate the patient's health....

Watch Now

Accelerate Your Pharma 4.0 Journey with Our Manufacturing Execution Systems (MES) Solution

video | May 5, 2022

Today’s pharmaceutical manufacturers face increasing pressure to deliver high-quality medicines quickly, efficiently and economically while complying with regulatory requirements and meeting sustainability goals....

Watch Now

Protein-Targeting Small Molecule Drug Screening-Preview

video | May 26, 2022

A Rapid and Quantitative Fluorimetric Method for Protein-Targeting Small Molecule Drug Screening - a 2 minute Preview of the Experimental Protocol...

Watch Now

Spotlight

Alnylam Pharmaceuticals

We are developing an innovative, entirely new class of medicines called “RNAi therapeutics” to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNA interference (RNAi), and a bold vision that this discovery could be used to silence disease-causing genes upstream of today’s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn’t have to wait for hope.

Events